Our study not only provides great insight into how LKB1 kinase activity is prohibited in NSCLC, but also offers new therapeutic strategies for targeting JOSD2 in NSCLC patients with JOSD2 inhibitors. The gene discussed is JOSD2; the disease is non-small cell lung carcinoma.